A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Who May Qualify: - fasting serum LDL-C ≥ 70 mg/dL (≥1.81 mmol/L) - Have fasting TG ≥150 mg/dL (≥1.7 mmol/L) and \<400 mg/dL (\<4.5 mmol/L) - Know diagnosis of T2DM OR have metabolic syndrome defined as fasting TG ≥150 mg/dL (≥1.7mmol/L) and \<400 mg/dL (\<4.5 mmol/L) and at least 2 risk factors - Are on stable guideline-recommended lipid-lowering therapy - Estimated glomerular filtration rate ≥15 mL/min/1.73 m2 Who Should NOT Join This Trial: - Have current or any previous history of New York Heart Association class III or IV heart failure or left ventricular ejection fraction \<30% - Have been hospitalized for heart failure within 5 years prior to Screening - Have uncontrolled severe hypertension - Have a formal diagnosis of homozygous familial hypercholesterolemia - HbA1c ≥10.0% (≥0.100 hemoglobin fraction) or a fasting glucose ≥270 mg/dL (≥15.0 mmol/L) at Screening - active liver disease Always talk to your doctor about whether this trial is right for you.